. 2015 Oct 26;16:172. doi: 10.1186/s12882-015-0170-x

Table 1.

Study assessments

	Screening	Psychiatric interview	Entry to clinical trial	1-2 weeks	1 month	2 months	3 months	4 months	5 months	6 months
Informed Consent	X	X	X
Inclusion/exclusion criteria fulfilled	X	X	X
Demographics	X
Co-morbid conditions (self-report)	X
Charlson Co-morbidity Index [29]			X		X	X	X	X	X	X
Brief psychiatric history	X
BDI-II [23]	X									X
PHQ-9 [26]	X			X	X	X	X	X	X	X
P4 Suicidality Screener [33]				X	X		X		X
Psychiatric Assessment		X		X		X		X		X
Montgomery- Asberg Depression Rating Scale [25]		X				X		X		X
Mini International Neuropsychiatric Interview [24]		X
List of medications			X		X	X	X	X	X	X
Description of dialysis treatment			X		X	X	X	X	X	X
Mid-week pre and post dialysis blood pressure	X		X		X	X	X	X	X	X
Dry weight	X		X		X	X	X	X	X	X
Adherence to dialysis treatment	X		X		X	X	X	X	X	X
Interdialytic weight gain	X		X		X	X	X	X	X	X
Urine volume per 24 h	X
Dialysis adequacy Kt/V	X		X		X	X	X	X	X	X
Dialysis time	X		X		X	X	X	X	X	X
Urea & electrolytes^a	X		X		X	X	X	X	X	X
Full blood count^b	X		X		X	X	X	X	X	X
Liver function tests^c			X		X	X	X	X	X	X
Electrocardiogram			X			X		X		X
IMP review					X	X	X	X	X	X
Drug compliance				X	X	X	X	X	X	X
Sertraline Plasma blood test								X
Baseline assessment of signs and symptoms			X
Adverse events				X	X	X	X	X	X	X
Kidney Disease QoL questionnaire [30]			X			X		X		X
Euroqol EQ 5D questionnaire [22, 31]			X			X		X		X
Clinical Global Impression Severity Scale [28]		X				X		X		X
Clinical Global Impression Improvement Scale [28]						X		X		X

^aUrea, Creatinine, Calcium, Sodium, Potassium and Bicarbonate

^bHaemoglobin, White blood cell count and platelets

^cBilirubin, Albumin, Alanine transaminase (ALT), Aspartate transaminase (AST), Aspartate Aminotransferase, Calcium, Phosphate and C-Reactive Protein